Rosacea - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Rosacea Emerging Therapy and TPP Insights

Thelansis's "Rosacea Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Rosacea Overview

Rosacea is a chronic inflammatory skin disorder involving neurovascular dysregulation, innate immune activation, barrier dysfunction, and, in some phenotypes, Demodex-associated inflammation. It commonly presents with persistent centrofacial erythema, flushing, telangiectasia, papules and pustules, with ocular and phymatous involvement in some patients. Management is phenotype-directed and includes photoprotection, topical ivermectin, metronidazole or azelaic acid, and brimonidine or oxymetazoline for persistent erythema. Low-dose doxycycline is used for inflammatory lesions, while lasers or surgery may address selected features. Minocycline ER (Emrosi) was FDA-approved in 2024 for inflammatory lesions in adults. Despite effective therapies, rosacea often requires long-term maintenance and can relapse. Development continues to explore anti-inflammatory, neurovascular, barrier, and microbiome-related mechanisms, with priorities including durable control and personalized care approaches.

Key Highlights

• In Germany, diagnosed Rosacea cases are projected to increase from 2,501,746 in 2025 to 2,819,254 by 2035.
• Rosacea is a chronic inflammatory skin disorder characterized by persistent facial erythema, flushing, and inflammatory lesions.
• The disease significantly impacts patients' quality of life, with frequent relapses requiring long-term management.
• Significant unmet need remains for therapies that provide sustained symptom control and reduce disease recurrence.

Market Overview

• The France Rosacea market is projected to grow from $48M in 2025 to $98M by 2035.
• Market growth is driven by:
• Increasing diagnosis and disease awareness
• Growing adoption of targeted topical and systemic therapies
• Future growth will depend on therapies offering durable disease control and improved patient outcomes.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• CAGE Bio Inc.
• Tarsus Pharmaceuticals, Inc.